An Albert Einstein College of Medicine-led study shows Rimegepant eliminated or materially decreased migraine symptoms and could provide an alternative to present medications on the market if approved by the Food and Drug Administration (FDA).
With over 1,000 participants struggling with migraines, they were assigned either rimegepant or placebo tablets. During the study patients tracked pain levels prior to taking the drug and 48 hours thereafter. Pain severity choices ranged from intolerance to light intolerance to loudness to nausea.
19.6 of patients taking rimegepant pills had no pain versus the 12% from the placebo group. About 38% of participants on rimegepant reported relief from migraine symptoms.
Richard B. Lipton, investigator with Albert Einstein College of Medicine and the study’s first author noted “For the first time in nearly three decades, people with migraine not helped by existing medications may have a new option to find relief during attacks.”
Known as BHV-3000, formally BMS-927711) is an investigational drug for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven
New Care Standard?
Should the drug be approved, it could take the place of triptan for select patients. Triptan is used to prevent migrations by activating serotonin receptors—triggering the narrowing of blood vessels and gradual reduction in inflammation. Constricting blood vessels may pose other risks to people with cardiovascular disease.
Rimegepant appears to only cause some nausea with some people and some other minimal side effects. The drug appears to be safe for cardiovascular patients.
A large Demand
The U.S. Department of Health and Human Services estimates that nearly 30 million have migraines of some kind and 75% of these patients are women.
Richard B. Lipton, investigator with Albert Einstein College of Medicine